Individualising first line treatment for advanced kidney cancer

In recent years, a number of new, effective treatments have become available for advanced kidney cancer. However, with more drugs available it has become more difficult to decide which drugs to choose for particular patients, and in which order to use them. In addition, the new treatments do not work for all patients and they […]

read more

Selecting therapy for poor-risk advanced kidney cancer

In this video interview, Dr Earle Burgess from the Levine Cancer Centre in the USA talks about the factors that are considered when selecting therapy for patients with poor-risk advanced renal cell carcinoma (RCC). Such factors include the risk status of the patient, burden or sites of disease, co-morbidities such as hypertension and cardiac disease, […]

read more

Rational approaches to treatment duration with immunotherapy for kidney cancer

A recent review of the use of immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma (RCC) was published in European Urology Focus this month. The use of immune checkpoint inhibitors has revolutionised the treatment of metastatic RCC over recent years. However, the appropriate duration of treatment with immune checkpoint inhibitors, such as […]

read more

Individualised treatment plans improve outcomes for kidney cancer

Over the past couple of years there have been several approvals of new treatments and drug combinations for advanced/metastatic renal cell carcinoma (RCC) resulting in treatment plans that are tailored for the individual patient. Recent advances in the treatment of advanced/metastatic RCC include cabozantinib, nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib. Dr Ajjai Shivaram Alva, associate professor at […]

read more

Personalised immunotherapy for advanced kidney cancer

In this video interview, Dr David Braun from the Dana-Farber Cancer Institute in Boston, USA, discusses his innovative research in metastatic kidney cancer, which focuses on understanding and improving immunotherapies in kidney cancer. He is working to develop novel immune-based treatments to personalise immunotherapy to overcome resistance to treatment. His work aims to better understand […]

read more

Data-driven approach to personalised care

One of the greatest strengths of the NHS is its comprehensive datasets of the population from birth to death. A recent paper proposes a new model of cancer care and looks at how data could be examined and used at every stage of the treatment journey, from prevention and diagnosis through to treatment and recovery. […]

read more

NHS to fast-track cancer drugs that target genetic mutations

The NHS is preparing to fast-track the introduction of ‘game changing’ new cancer drugs that target tumours according to their genetic make-up. These revolutionary new treatments, called ‘tumour agnostic’ drugs, can be used against a wide range of cancers and could offer hope to patients with rare cancers that may previously have been untreatable. Tumour […]

read more

Personalised vaccine to be tested in patients with kidney cancer

Scientists at the Dana-Farber Cancer Institute in Boston, USA, are testing a new personalised cancer vaccine, called NeoVax, for the treatment of kidney cancer patients at high risk of recurrence following surgery. The vaccine incorporates proteins (neoantigens) that are specific to the cancer cells in each individual’s tumour. The vaccine is then linked to a […]

read more

New artificial intelligence technique could help predict how cancer will mutate

New research, published in the journal Nature Methods, describes a new artificial intelligence (AI) technique that could help doctors predict how cancer tumours will mutate, and eventually allow them to personalise each individual’s treatment earlier. The research was conducted at The Institute of Cancer Research (ICR) in London, and has resulted in the development of […]

read more

Personalised management of advanced kidney cancer

A recent article published in the 2018 American Society of Clinical Oncology Educational Book, summarises the advances made towards personalised management of advanced renal cell carcinoma (RCC). The researchers suggest that “Individualised care using predictive biomarkers is central to the treatment of other advanced malignancies,” and “The elucidation of predictive factors is an unmet need in metastatic […]

read more
Showing 1 to 10 of 13 results
  TOP